AIMS/HYPOTHESIS: Natural killer (NK) cells serve as primary immune surveillance and are partially regulated by combinations of killer immunoglobulin-like receptor (KIR) genes and their HLA class I ligands. Alterations in NK cell activity have been associated with type 1 diabetes. The aim of this study was to determine whether KIR-HLA class I gene frequency: (1) is altered in a current population with type 1 diabetes compared with healthy controls; and (2) has changed over the half century in which the incidence of type 1 diabetes has increased rapidly. METHODS: KIR-HLA class I gene frequencies were compared in 551 individuals diagnosed with type 1 diabetes ≤ 15 years of age (394 in a current cohort and 157 from the historical 'Golden Years' cohort) and 168 healthy controls. The overall balance of activation and inhibition was analysed using KIR-HLA genotype models. RESULTS: Children with type 1 diabetes who were positive for KIR2DS2/KIR2DL2 and KIR2DL3 were more often homozygous for HLA-C group 1 and this effect was strongest in children diagnosed with diabetes before the age of 5 years (p = 0.003, corrected p [p (corr)] = 0.012) and (p = 0.001, p (corr) = 0.004), respectively. Children with type 1 diabetes have fewer inhibitory KIRs with their corresponding ligands compared with healthy controls (p = 1.9 × 10(-4)). This pattern of NK activation has not changed significantly in individuals with type 1 diabetes over the last half century. CONCLUSIONS/ INTERPRETATION: Activating combinations of KIR-HLA genes are more frequent in young children with type 1 diabetes diagnosed in the first 5 years of life, suggesting that NK cell responses may be altered in this group.
AIMS/HYPOTHESIS: Natural killer (NK) cells serve as primary immune surveillance and are partially regulated by combinations of killer immunoglobulin-like receptor (KIR) genes and their HLA class I ligands. Alterations in NK cell activity have been associated with type 1 diabetes. The aim of this study was to determine whether KIR-HLA class I gene frequency: (1) is altered in a current population with type 1 diabetes compared with healthy controls; and (2) has changed over the half century in which the incidence of type 1 diabetes has increased rapidly. METHODS: KIR-HLA class I gene frequencies were compared in 551 individuals diagnosed with type 1 diabetes ≤ 15 years of age (394 in a current cohort and 157 from the historical 'Golden Years' cohort) and 168 healthy controls. The overall balance of activation and inhibition was analysed using KIR-HLA genotype models. RESULTS: Children with type 1 diabetes who were positive for KIR2DS2/KIR2DL2 and KIR2DL3 were more often homozygous for HLA-C group 1 and this effect was strongest in children diagnosed with diabetes before the age of 5 years (p = 0.003, corrected p [p (corr)] = 0.012) and (p = 0.001, p (corr) = 0.004), respectively. Children with type 1 diabetes have fewer inhibitory KIRs with their corresponding ligands compared with healthy controls (p = 1.9 × 10(-4)). This pattern of NK activation has not changed significantly in individuals with type 1 diabetes over the last half century. CONCLUSIONS/ INTERPRETATION: Activating combinations of KIR-HLA genes are more frequent in young children with type 1 diabetes diagnosed in the first 5 years of life, suggesting that NK cell responses may be altered in this group.
Authors: Kathleen M Gillespie; Steven C Bain; Anthony H Barnett; Polly J Bingley; Michael R Christie; Geoffrey V Gill; Edwin A M Gale Journal: Lancet Date: 2004 Nov 6-12 Impact factor: 79.321
Authors: Izortze Santin; Guiomar Pérez de Nanclares; Begoña Calvo; Ayman Gaafar; Luis Castaño; Jose Ramon Bilbao Journal: Hum Immunol Date: 2006-04-05 Impact factor: 2.850
Authors: M Uhrberg; N M Valiante; B P Shum; H G Shilling; K Lienert-Weidenbach; B Corliss; D Tyan; L L Lanier; P Parham Journal: Immunity Date: 1997-12 Impact factor: 31.745
Authors: K Negishi; N Waldeck; G Chandy; B Buckingham; A Kershnar; L Fisher; S Gupta; M A Charles Journal: Diabetologia Date: 1986-06 Impact factor: 10.122
Authors: Susan E Hiby; James J Walker; Kevin M O'shaughnessy; Christopher W G Redman; Mary Carrington; John Trowsdale; Ashley Moffett Journal: J Exp Med Date: 2004-10-11 Impact factor: 14.307
Authors: Lin Lin; Chao Ma; Bo Wei; Najib Aziz; Raja Rajalingam; Susy Yusung; Henry A Erlich; Elizabeth A Trachtenberg; Stephan R Targan; Dermot P B McGovern; James R Heath; Jonathan Braun Journal: J Immunol Date: 2014-06-16 Impact factor: 5.422
Authors: Juan Huang; James Alexander Pearson; F Susan Wong; Li Wen; Zhiguang Zhou Journal: Diabetes Metab Res Rev Date: 2021-06-22 Impact factor: 4.876
Authors: Awad E Osman; Imad Brema; Alaa AlQurashi; Abdullah Al-Jurayyan; Benjamin Bradley; Muaawia A Hamza Journal: Int J Immunopathol Pharmacol Date: 2022 Jan-Dec Impact factor: 3.219
Authors: Nikolas Pontikos; Deborah J Smyth; Helen Schuilenburg; Joanna M M Howson; Neil M Walker; Oliver S Burren; Hui Guo; Suna Onengut-Gumuscu; Wei-Min Chen; Patrick Concannon; Stephen S Rich; Jyothi Jayaraman; Wei Jiang; James A Traherne; John Trowsdale; John A Todd; Chris Wallace Journal: BMC Genomics Date: 2014-04-11 Impact factor: 3.969